Hypoxia in the Tumor Immune Microenvironment (TIME)

We will review our recent in vivo (e.g. PET/MR) and cellular and molecular (e.g. MRI/NMR spectroscopy) preclinical studies that provide new insights of varied tumor profiles/types and the underlying interplay in PD-L1 status, hypoxia, and fibroblasts in the tumor microenvironment. Such insights pave the way for improved therapies.
Certain cancers may exhibit treatment resistance to modern therapies including checkpoint inhibitors. In many cases, aspects of the tumor microenvironment can influence how aggressive a tumor is and/or correlate with underlying treatment resistance. Several tumor microenvironment biomarkers have been correlated with cancer aggression and patient outcomes, including tumor pH, hypoxia, and angiogenesis.
Here, we will review in vivo (e.g. PET/MR) and cellular and molecular (e.g. MRI/NMR spectroscopy) preclinical studies that provide new insights of varied tumor profiles/types and the underlying interplay in PD-L1 status, hypoxia, and fibroblasts in the tumor microenvironment. Such insights pave the way for improved therapies.
This topic will be relevant to researchers involved in PET tracer development, cancer biology and therapeutics, and specifically nuclear imaging specialists.

Register here